Cardio-oncology includes the intersection of heart conditions in patients who have been treated for cancer. The cardio oncology filed is growing at a faster rate because the survivors after cancer treatment are more prone to cardiac disorders. The increase in cancer disease in the world has led to the emergence of numerous chemotherapeutic agents which are under preclinical or clinical studies. These agents are potent to cause damage to the heart (cardio-toxicity). Cardio-toxic effects of chemotherapy might be decreased by the concurrent use of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers or beta-blockers. The use of diagnostic imaging, non-invasive stress testing, serum biomarkers, ambulatory blood pressure monitoring and ambulatory cardiac telemetry can help to identify cardio-toxicities and lead to the development of preventative strategies.